• 1
    Feinstein AR. Principles and practice of clinimetrics in epilepsy. In: MeinardiH, CramerJA, BakerCA, Martins da SilvaA, eds. Quantitative assessment in epilepsy care. New York : Plenum Press, 1993:110.
  • 2
    Taveira MC, Martins da Silva A, Mena Matos P, Borges IP, Canijo M, Mendonça D. Self-esteem and epilepsy: a comparative study in a Portuguese population. Bol Epilepsy 1994;1:1926.
  • 3
    EngelJJr, ed. Surgical treatment of the epilepsies. New York : Raven Press, 1987.
  • 4
    RiedS, SiemesH, ShorvonS, eds. Diary E. Berlin : Blackwell Science, 1997.
  • 5
    Besag FMC, Mills M, Wardale F, Andrew CM, Craggs MD. The validation of a new ambulatory spike and wave monitor. Electroencephalogr Clin Neurophysiol 1989;73:15761.
  • 6
    Feinstein AR. Clinimetrics. New Haven , CT : Yale University Press, 1987.
  • 7
    Cramer JA, Smith DB, Mattson RH, Delgado-Escueta AV, Collins JF, and The VA. Epilepsy Cooperative Study No. 118 Group. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983;33(suppl 1):2637.
  • 8
    Cramer JA, Mattson RH. Quantitative approaches to seizure severity. In: MeinardiH, CramerJA, BakerGA, Martins da SilvaA, eds. Quantitative assessment in epilepsy care. New York : Plenum Press, 1993:5571.
  • 9
    Baker GA, Smith DF, Dewey M, Morrow J, Crawford PM, Chadwick DW. The development of a seizure severity scale as an outcome measure in epilepsy. Epilepsy Res 1991;8:24551.
  • 10
    O'Donoghue MF, Duncan JS, Sander JWAS. The National Hospital Seizure Severity Scale: a further development of the Chalfont Seizure Severity Scale. Epilepsia 1996;37:56371.
  • 11
    Duncan JS, Sander JWAS. The Chalfont Seizure Severity Scale. J Neurol Neurosurg Psychiatry 1991;54:8736.
  • 12
    Wijsman DJP, Hekster YA, Keyser A, Renier WO, Meinardi H. Clinimetrics and epilepsy care. Pharm Weekbl [Sci] 1991;13:1828.
  • 13
    Smith D, Baker G, Davies G, Dewey M, Chadwick D. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:31222.
  • 14
    Wagner AK, Keller SD, Kosinski M, et al. Advances in methods for assessing the impact of epilepsy and antiepileptic drug therapy on patients' health-related quality of life. QOL Res 1995;4:11534.
  • 15
    Carpay JA, Vermeulen J, Stroink H, et al. Parent-completed scales for measuring severity of seizures and side effects of antiepileptic drugs in childhood epilepsy: development and psychometric analysis. Epilepsy Res 1996;24:17381.
  • 16
    Nakazawa Y, Ishida S, Maeda H, Sakurai S, Motooka H. Prognosis of epilepsy withdrawn from antiepileptic drugs. Psychiatry Clin Neurosci 1995;49:1638.
  • 17
    Lynch BJ, O'Tuama LA, Treves ST, Mikati M, Holmes GL. Correlation of 99mTc-HMPAO SPECT with EEG monitoring: prognosis value for outcome of epilepsy surgery in children. Brain Dev 1995;17:40917.
  • 18
    Ortibus EL, Sum JM, Hahn JS. Predictive value of EEG for outcome and epilepsy following neonatal seizures. Electroencephalogr Clin Neurophysiol 1996;98:17585.
  • 19
    Lopes da Silva FH, Pijn JP, Wadman WJ. Dynamics of local neuronal networks: control parameters and state bifurcations in epileptogenesis. In: vanPeltJ, CornerMA, UylingsHBM, Lopes da SilvaFH, eds. Progress in brain research, vol. 102. Amsterdam : Elsevier Science BV, 1994:35970.
  • 20
    Lopes da Silva FH, Pijn JP, Velis DN. Signal processing of EEG: evidence for chaos or noise, an application to seizure activity in epilepsy. In: GathI, InbarGF, eds. Advances in processing and pattern analysis of biological signals. New York Plenum Press, 1996:2131.
  • 21
    Shouse MN, Martins da Silva A, Sammaritano M. Circadian rhythm, sleep, and epilepsy. J Clin Neurophysiol 1996;13:3250.
  • 22
    Martins da Silva A, Lourenço E, Nunes JM, Mendonça D. Seizure frequency as treatment effect parameter. In: MeinardiH, CramerJA, BakerGA, Martins da SilvaA, eds. Quantitative assessment in epilepsy care. New York : Plenum Press, 1993:3542.
  • 23
    Wu X, Xiao CH. Quantitative pharmaco-EEG of carhamazepine in volunteers and epileptics. Clin Electroencephalogr 1996;27:405.
  • 24
    Chen YJ, Kang WM, So WC. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study. Epilepsia 1996;37:816.
  • 25
    Roehrs T, Roth T. Multiple sleep latency test: technical aspects and normal values. J Clin Neurophysiol 1992;11:637.
  • 26
    Johns MW. A new method for measuring daytime sleepiness; The Epworth Sleepiness Scale. Sleep 1991;14:6405.
  • 27
    Binnie CD. Methods of detecting transitory cognitive impairment during epileptiform EEG discharges. In: DodsonWE, KinsbourneM, HiltbrunnerB, eds. The assessment of cognitive function in epilepsy. New York : Demos Publications, 1991:12736.
  • 28
    Mattson RH, Cramer JA. Quantitative assessment of adverse drug effects. In: MeinardiH, CramerJA, BakerGA, Martins da SilvaA, eds. Quantitative assessment in epilepsy care. New York : Plenum Press, 1993:12335.
  • 29
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:14551.
  • 30
    Mattson RH, Cramer JA, Collins JF, and The VA. Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:76571.
  • 31
    Gillham R, Baker G, Thompson P, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Epilepsy Res 1996;24:4755.
  • 32
    Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995;22:6595.
  • 33
    Cochran H, Maston A, Baker GA, Chadwick DW. Neuropsychological outcomes in randomised clinical trials of antiepileptic medication: a systematic review. 1998 (in press).
  • 34
    Dodrill CB. A neuropsychological battery for epilepsy. Epilepsia 1978;19:61123.
  • 35
    Alpherts WCJ, Aldenkamp AP. Computerized neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990;31(suppl 4):S3540.
  • 36
    Aldenkamp AP, Baker G, Pieters MSM, Schoemaker HC, Cohen AF, Schwabe S. The Neurotoxicity Scale: the validity of a patient-based scale, assessing neurotoxicity. Epilepsy Res 1995 20:22939.
  • 37
    Deckers CLP, Hekster YA, Keyser A, Meinardi H, Renier WO. Reappraisal of polytherapy in epilepsy: a critical review of drug-load and adverse effects. Epilepsia 1997;38:5705.
  • 38
    Hays RD, Sherbourne C, Mazel E. The RAND 36–item health survey 1.0. Health Econ 1993;2:21727.
  • 39
    Ware JE, Sherbourne CD. A 36–item Short Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:47383.
  • 40
    Tarlov AR, Ware JE, Greenfield S, et al. The Medical Outcomes Study: an application of methods for monitoring the results of medical care. JAMA 1989;262:92530.
  • 41
    , Hunt S, McKenna J, McKenna SP. The Nottingham Health Profile: user's manual, 1981.
  • 42
    Bergner M. Development, testing, and use of the Sickness Impact Profile. In: WalkerSR, RosserMR, eds. Quality of life: assessment and application. Lancaster : MTP Press, 1988:7984.
  • 43
    Nelson EC, Landgraf JM, Hays RD, Wasson JH, Kirk JW. The functional status of patients: how can it he measured in physicians' offices Med Care 1990;28:111126.
  • 44
    EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199208.
  • 45
    Baker GA, Smith DF, Dewey M, et al. The initial development of a health-related quality of life model as an outcome measure in epilepsy. Epilepsy Res 1993;16:6581.
  • 46
    Bradburn NM. The structure of psychological well-being. Chicago : Aldine, 1969.
  • 47
    Rosenberg M. Society and the adolescent self-image. Princeton : Princeton University Press, 1965.
  • 48
    Pearlin L, Schooler C. The structure of coping. J Health Soc Behav 1978;19:221.
  • 49
    Hyman MD. The stigma of stroke. Geriatrics 1971;5:13241.
  • 50
    Jacoby A, Baker GA, Smith DF, Dewey M, Chadwick DW. Measuring the impact of epilepsy: the development of a novel scale. Epilepsy Res 1993;16:838.
  • 51
    Baker GA, Jacoby A, Smith DF, Dewey ME, Chadwick DW. The development of a novel scale to assess life fulfillment as part of the further refinement of a quality of life model for epilepsy. Epilepsia 1994;35:5916.
  • 52
    Vickrey BG, Hays RD, Graber J, Rausch R, Engel J, Brook RH. A health-related quality of life instrument for patients evaluated for epilepsy surgery. Med Care 1992;30:299319.
  • 53
    Vickrey BG. A procedure for developing a quality-of-life mea sure for epilepsy surgery patients. Epilepsia 1993;34(suppl 4):S227.
  • 54
    Devinsky O, Vickrey BG, Cramer JA, Perrine K, Hermann B, Meador K, Hays RD. Development of the quality of life in epilepsy inventory. Epilepsia 1995;36:1089104.
  • 55
    Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. Development and cross-cultural translations of a 31–item quality of life in epilepsy inventory (QOLIE-31). Epilepsia (in press).
  • 56
    Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy. The QOLIE-10. Epilepsia 1996;37:57782.
  • 57
    Hoare P, Russell M. The quality of life of children with chronic epilepsy and their families: preliminary findings with a new assessment measure. Dev Med Child Neurol 1995;37:68996.
  • 58
    Cramer JA. Quality of life as an outcome measure for epilepsy: clinical trials. Pharmacy World Sci 1997;19:22730.
  • 59
    Leber P. Hazards of inference. The active control investigation. Epilepsia 1989;30:S5763.
  • 60
    Cereghino JJ. Clinical trial design for antiepileptic drugs. Ann Neurol 1992;32:3934.
  • 61
    Pledger G, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia 1991;32:71631.
  • 62
    Gram L, Schmidt D. Innovative designs of controlled clinical trials in epilepsy. Epilepsia 1993;34(suppl 7): 16.
  • 63
    Johnson AL. Statistical aspects of the measurement of clinical care in epilepsy. In: MeinardiH, CramerJA, BakerGA, Martins da SilvaA, eds. Quantitative assessment in epilepsy care. New York : Plenum Press, 1993:1128.
  • 64
    Eadie MJ. Problems in the assessment of potential antiepileptic drugs. CNS Drugs 1994;1:16771.
  • 65
    Leber P. The implicit assumptions of active controlled trials (a critical examination). Control Clin Trials 1983;14:133.
  • 66
    Perucca E. Monotherapy with the new antiepileptic drugs: test protocols, experience and indications. In: StefanH, ed. Challenges in epilepsy: new antiepileptic drugs. Berlin : Blackwell Wissenschaft (in press).
  • 67
    Beghi E, Perucca E. The management of epilepsy in the 1990s. Acquisitions, uncertainties and perspectives for future research. Drugs 1995;49:68094.
  • 68
    Devinsky O, Faught RE, Wilder BJ, et al. Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res 1995;20:2416.
  • 69
    Sachdeo SK, Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate double-blind trial as monotherapy. Epilepsia 1995;36(suppl 4):33.
  • 70
    Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995;36(suppl 6):26.
  • 71
    Lamoureaux L, Garofalo EA, Crockat JG, and the US Gabapentin Study Group 88/89. Gabapentin (Neurontin) monotherapy in men versus women and in patients receiving previous monotherapy versus those receiving previous polytherapy. Epilepsia 1996; 37(suppl 4):69.
  • 72
    Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992;32:38692.
  • 73
    Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active control trial. Neurology 1993;43:68892.
  • 74
    Bourgeois B, Leppik IE, Sackellares JC, Laxer K, Lesser R. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993;43:6936.
  • 75
    Eslava-Cobos J. Objective measure of treatment outcome in epilepsy. Epilepsia 1996;37:5726.
  • 76
    Ahmad S, Perucca E, Richens A. The effect of frusemide, mexiletine, (+)- propranolol and three benzodiazepine drugs on interictal spike discharges in the electroencephalograms of epileptic patients. Br J Clin Pharmacol 1977;4:6838.
  • 77
    Kasteleijn-Nolst Trenité DGA, van Emde Boas W, Greenhout CM, Meinardi H. Preliminary assessment of the efficacy of Org 6370 in photosensitivity and provocation of myoclonic seizures. Epilepsia 1992;33:13541.
  • 78
    Dam M, Ekberg R, Løvning Y, Waltimo O, Jacobsen J. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:707.
  • 79
    Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry 1994;57:6827.
  • 80
    Steiner TJ. Comparison of lamotrigine and phenytoin mono therapy in newly diagnosed epilepsy. Epilepsia 1994;35(suppl 8):31.
  • 81
    Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995;58:4450.
  • 82
    Verity CM, Hosking G, Easter DJ (on behalf of The Pediatric EPITEG Collaborative Group). A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995;37:97108.
  • 83
    de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:70913.
  • 84
    Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345:4769.
  • 85
    Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized controlled study. Arch Neurol 1995;52:98996.
  • 86
    Reunanen M, Dam M, Yuen AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:14955.
  • 87
    Chadwick DW, Roi L, Kennedy KM. Vigabatrin (Sabril) as first-line monotherapy in newly diagnosed epilepsy: a double-blind comparison with carbamazepine. Epilepsia 1996;37(suppl 4):6.
  • 88
    Deckers CLP, Hekster YA, Keyser A, Lammers MW, Meinardi H, Renier WO. Adverse effects in epilepsy therapy. Wait and see or go for it Acta Neurol Scand 1997;95:24852.
  • 89
    Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier WO, van Lier H. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995;36:4406.
  • 90
    Louik C, Lacouture PG, Mitchell AA, et al. A study of adverse drug reaction algorithms in a drug surveillance program. Clin Pharmacol Ther 1985;38:1837.
  • 91
    Arbeitskreis zur Verbesserung der Eingliederungschancen von Personen mit Epilepsie: Empfehlungen zur Beurteilung beruflicher Möglichkeiten von Personen mit Epilepsie-Überarbeitung 1994. Die Rehabil 1994;33:1718.
  • 92
    Anonymous. National Institutes of Health Consensus Conference. Surgery for epilepsy. JAMA 1990;264:72933.
  • 93
    Wiebe S, Rose K, Derry P, McLachlan R. Outcome assessment in epilepsy: comparative responsiveness of quality of life and psychosocial instruments. Epilepsia 1997;38:4308.
  • 94
    Dodrill CB, Batzel LW, Fraser RT. Psychosocial changes after surgery for epilepsy. In: LüdersH, ed. Epilepsy surgery. New York : Raven Press, 1991:661.
  • 95
    Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia 1997; 38:15463.
  • 96
    Vickrey BG, Hays RD, Engel J. Outcome assessment for epilepsy surgery: the impact of measuring health-related quality of life. Ann Neurol 1995;37:15866.
  • 97
    Devinsky O. Outcome research in neurology: incorporating health-related quality of life. Ann Neurol 1995;37:1412.
  • 98
    Camfield PR, Camfield CS. Acute and chronic toxicity of antiepileptic drugs: a selective review. Can J Neurol Sci 1994;21(suppl 3):S711.
  • 99
    Camfield CS, Camfield PR, Smith E, Tibbles JAR. Asymptomatic children with epilepsy: little benefit from screening for anticonvulsant-induced liver, blood, or renal damage. Neurology 1986;36:83841.
  • 100
    Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Franklin Herlong H. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:7227.
  • 101
    Camfield PR, Camfield CS, Dooley I. Farrell K, Humphreys P. Langevin P. Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value. Can Med Assoc J 1989;140:2815.
  • 102
    Gordon KE, Bawden H, Camfield PR, Orlik P, Mann S. Treatment of learning disorder and severely epileptiform EEG without clinical seizures using valproic acid: a double blind, randomized, N of 1 clinical trial. J Child Neurol 1996;11:413.